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MATERIALS AND METHODS
Cardiac cell culture. Cardiac cells were dissociated from 1-day-old Wistar rat pups with 0.1% trypsin. To selectively enrich for myocytes, dissociated cells were preplated in a cabinet at 37°C with 5% CO 2 for 1 h. The nonmyocytes attached readily to the bottom of the culture dish (21, 27) . The resultant suspension of myocytes was plated into culture dishes at a density of 5 ϫ 10 5 cells/ml. One hundred micromolar bromodeoxyuridine was added during the first 24-36 h to prevent proliferation of nonmyocytes (26) . Using this method, we routinely obtained cultures with ϳ95% myocytes, as assessed by microscopic observation of cell beating.
Cells adherent to the culture dishes during the preplating procedure were resuspended with culture medium and then allowed to reattach for 30 min at 37°C. After two repetitions of this procedure, the cells were distributed into culture dishes and incubated in the culture medium described above, except for using 10% calf serum without bromodeoxyuridine. In the third passage, the cells were mainly cardiac fibroblasts (21) . Cells in the third or fourth passage were used for experiments.
Cell proliferation assay. Subconfluent nonmyocytes were seeded in 96-well plates at a density of 4,000 cells per well and cultured for 12 h in the presence of 10% calf serum. Subsequently, cells were washed twice with serum-free medium and growth arrested in the serum-free medium for 24 h. Then the quiescent cells were treated with ANG II and/or atRA for 24 h. ANG II was supplemented at 12 h to compensate for a decrease due to degradation by endogenous angiotensinase. Control cultures contained DMSO vehicle. To terminate the experiment, the plates were rinsed twice with 0.8 ml of PBS, fixed with 4% formaldehyde for 1 h, washed twice with PBS, stained with 0.5% crystal violet for 2 h, distained with distilled water, and solubilized in 36% acetic acid. Absorbency at 650 nm was measured on a multiwell scanning spectrophotometer. Absorbency at 650 nm was directly proportional to the number of cells in the wells (8) . Results were presented as means Ϯ SE of multiple cultures.
Quantification of total cell protein content. Myocytes collected from primary cell cultures were suspended in culture medium, and cell numbers were counted for four times. Same amounts of cell suspension were seeded in each well of the six-well plates. After incubation in serum-free medium for 24 h, cardiac myocytes were stimulated with ANG II (100 nM) for 5 days in the presence of indicated concentrations of atRA. ANG II was supplemented every 12 h to compensate for the decrease due to degradation, and atRA was replenished when the culture medium was replaced with fresh serum-free medium every other day. Dishes were washed three times with chilled PBS to remove trace medium, and the cells were dissolved in 2% SDS (1 loading buffer). Protein concentrations were measured by a modification of the method of Lowry et al. (18) .
Analysis of MHC profile. Cultured myocytes were homogenized (1:10, wt/vol) in 75 mM Tris buffer, pH 6.8. The homogenate was placed in a 100°C heating block for 10 min and immediately placed on ice for 5 min. The sample was then vortexed and centrifuged at 12,000 rpm for 10 min. An aliquot of the supernatant was used to determine protein concentration by a modification of the method of Lowry et al. (18) , and the rest was used for SDS-PAGE or stored at Ϫ80°C for later use (13) .
The amount of total protein loaded on the gel was 10 g per lane. Each sample was combined with at least an equal volume of concentrated loading buffer, which contained 150 mM Tris (pH 6.8), 4% (wt/vol) SDS, 20% (vol/vol) glycerol, 10% (vol/vol) ␤-mercaptoethanol, and 0.001% bromphenol blue. Samples were boiled for 3 min, immediately placed on ice for 1 min, and centrifuged at 12,000 rpm for 5 min before loading the gel.
The stacking gels consisted of 5% glycerol, 4% acrylamide-N, NЈ-methylene-bis-acrylamide (bis) (50:1), 70 mM Tris (pH 6.8), 4 mM EDTA, and 0.4% SDS. Separating gels were composed of 5% glycerol, 8% acrylamide-bis (50:1), 200 mM Tris (pH 8.8), 100 mM glycine, and 0.4% SDS. The upper electrode buffer consisted of 0.1 M Tris (base), 150 mM glycine, 0.1% SDS, and 10 mM ␤-mercaptoethanol, and the lower electrode buffer of 50 mM Tris (base), 75 mM glycine, and 0.05% SDS (30) . The gel was run in a V-16 unit at 4°C. After electrophoresis, the gels were stained with Coomasie blue R-250 for at least 4 h and destained until the bands were apparent. Gels were photographed and subsequently placed in 30% glycerol for storage. The photographs were scanned and analyzed by using Leica image analysis system to determine the relative quantities of ␣-and ␤-MHC.
Ultramicroscopic structure observation. Cultured neonatal rat cardiac myocytes were detached from the cultured flasks and collected by centrifugation. The cells were fixed, dehydrated, infiltrated, and embedded in epoxy resin. Fifty-to sixty-nanometer ultra thin sections were cut on LKB-1 ultramicrotome and stained before they were observed and photographed by a JEM-1200 EX transmission electron microscopy.
Measurement of intracellular Ca 2ϩ levels. Cardiac myocytes were cultured on glass coverslips in serum-free medium. Before experiments, those coverslips were placed in a Petri dish containing 1 ml of serum-free medium. Fluo 3-AM loading of the cells was performed by adding 0.33 ml of labeling stock solution to the culture medium, which consisted of 10 parts of 1 mM fluo 3-AM in dry DMSO, 15 parts of 10% Pluronic F-127 solution, and 975 parts of culture medium containing 2% BSA. After the parts were mixed, the dishes were incubated in a cabinet containing 5% CO2 at 37°C for 30 min. After two repetitions, a coverslip containing fluo 3-loaded cells was mounted on the stage of a fluorescence microscope. The excitation wavelength was 500 nm, and the fluorescence signals emitted by the cells were observed and photographed by an auto-photography system. The signals remained stable for about 1.5 h at 28°C. The photographs were scaned and analyzed by a Leica image analysis system, and the results were presented as integrated fluorescence density. The background was determined with the nonlabeled cells (25) .
Statistical analysis. Data are given as means Ϯ SE. When data were amenable to statistical analysis, a one-way ANOVA was performed with Student-Newman-Keuls test for significance. Significance was accepted at P Ͻ 0.05.
RESULTS
Hyperplasia of nonmyocytes. ANG II induced a significant increase in cell number over 24 h in a dosedependent manner (Fig. 1A) . The values of absorbency in the wells of control and the wells treated with 10 Ϫ10 , 10 Ϫ9 , 10 Ϫ8 , and 10 Ϫ7 M ANG II were 0.1778 Ϯ 0.0096, 0.2032 Ϯ 0.0237, 0.2592 Ϯ 0.0189, 0.3147 Ϯ 0.0158, Although atRA alone has no effect on the growth of nonmyocytes, it can inhibit ANG II-induced hyperplasia of those cells (Fig. 1C) . The values of absorbency in the wells of control and the wells of 10 Ϫ7 , 10 Ϫ6 , and 10 Ϫ5 M atRA were 0.1778 Ϯ 0.0096, 0.1808 Ϯ 0.0133, 0.1772 Ϯ 0.0153, and 0.166 Ϯ 0.0199, respectively.
Myocyte protein content. Total protein content increased by 30% in the myocytes incubated with 10 Ϫ6 M ANG II for 5 days. Treatment with 10 Ϫ6 M atRA abolished this increase, and 10 Ϫ6 M atRA alone caused no significant change in protein content (Fig. 2) . The values of total protein content of the group of control and the groups of 10 Ϫ7 M ANG II, 10 Ϫ7 M ANG II ϩ 10 Ϫ6 M atRA, and 10 Ϫ6 M atRA were 1.520 Ϯ 0.104, 1.965 Ϯ 0.226, 1.592 Ϯ 0.172, and 1.639 Ϯ 0.161 g/ml, respectively. However, 10
Ϫ5 M atRA caused a significant reduction in protein content in not only the ANG II-treated group but also the control cultures. (Fig. 3) . There was no detectable effect of atRA on ANG II-induced shift in MHC profile within our dosage range.
Ultramicroscopic structure. In the control cells, there were some sparsely distributed Golgi complexes and sarcomeric fibers, but no typical Z band was observed (Fig. 4A) . Treated with ANG II (10 Ϫ7 M) for 5 days, the cultured neonatal rat cardiac myocytes demonstrated apparently an accumulation of Golgi complexes and nonparallel sarcomeric fibers as well as reorganization of the sarcomeric unit within individual myocytes (Fig.  4B) . atRA (10 Ϫ6 M) treatment reduced the accumulation of sarcomeric fibers without affecting the ANG II-induced reorganization of the sarcomeric unit (Fig.  4C ). There is no apparent difference in the quantity and distribution of sarcomeric fibers and Golgi's complexes between the cells treated with atRA alone and the control group (Fig. 4D) .
Intracellular Ca 2ϩ levels in cultured cardiac myocytes. 4 . Observation of the ultramicroscopic structure of cultured neonatal rat cardiac myocytes. Some Golgi complexes and sarcomeric fiber but no typical Z bands can be seen in control cells (A). In cells treated with ANG II (B), there were more Golgi complexes and sarcomeric fiber than in control cells, and many typical Z bands were observed. In ANG II ϩ atRA-treated myocytes (C), there were smaller amounts of Golgi complexes and sarcomeric fibers than in ANG II-treated myocytes, but they had a similar amount of Z bands. In atRA-treated myocytes (D), there was no apparent difference in the quantity and distribution of sarcomeric fibers and Golgi complexes when compared with control. dium with the potent capacity to proliferate and secrete collagen. Hyperplasia of cardiac fibroblasts is an important pathological phenomenon in cardiac hypertrophy and remodeling. During cardiac hypertrophy, cardiac fibroblasts are documented to proliferate and produce much collagen, which is accumulated in the extracellular matrix and, in turn, causes myocardial fibrosis and the dysfunction of the myocardium (29) . Our results showed that atRA can inhibit ANG IIinduced proliferation of the cardiac fibroblast. Taking the evidence that ANG II can directly activate collagen synthesis in isolated adult rat cardiac fibroblasts, we hypothesize that atRA has a beneficial effect on the remodeling process of cardiac extracellular matrix.
Myocyte protein content. The increase in protein content in the cardiac myocytes is an important character of cardiac hypertrophy and remodeling (23) . Sodashima and Izumo (24) reported that, in the cultured neonatal rat cardiac myocytes, treatment with ANG II for 5 days caused a dramatic increase in the protein content.
atRA plays an important role in cell growth and differentiation during development. It is documented that atRA plays a very important role in embryonic stem cell-derived cardiac differentiation and the development of ventricular cardiomyocytes (19, 33) . atRA has two nuclear receptors: rapidly adapting receptor (RAR) and retinoid X receptor (RXR). Both of these receptors can be further categorized into three subtypes: ␣, ␤, and ␥. RAR and RXR can form homodimers and heterodimers, which can bind DNA in the nucleus with high affinity. RXR can also form heterodimers with the thyroid and vitamin D 3 receptors, and play a wider role in various biological processes. In cardiovascular studies, research on RXR knockout mice provided direct evidence that RXR is essential in the development of heart in the homozygous RXR␣ knockout mice. Deletion of RAR (i.e., RAR␣ and RAR␥) was shown to amplify some features of the RXR␣ Ϫ/Ϫ phenotype, suggesting that retinoid receptor-signaled activity may converge at key points in embryogenesis to promote normal development of the cardiovascular system (11, 15, 28) .
In our study, atRA inhibited the increase in total protein content during ANG II-induced cardiac hypertrophy. There are also reports showing that atRA can inhibit other phenotypes in cardiac hypertrophy. Zhou et al. (36) reported that, in cultured neonatal rat cardiac myocytes, atRA suppressed phenyphrine and endothelin-1 (ET-1)-induced increase in cell size and induction of atrial natriuretic factor (ANF). Wu et al. (34) documented that atRA antagonized ET-1-induced ANF secretion and increase in cell size in cultured neonatal rat cardiac myocytes.
When it comes to the receptor type (RAR or RXR) by which atRA inhibits cardiac hypertrophy, there are contradictory receptors. Zhou et al. (36) showed that it is through RARs that atRA inhibit phenylephrine-induced ANF secretion. However, the results of Wu et al. are contradictory to those of Zhou et al., and Wu et al. concluded that it is not RARs but RXRs that mediate the inhibitory effects of atRA on ET-1-induced cardiac hypertrophy (34) .
Cardiac MHC profile. Between 12 and 24 h after hypertrophic stimulation, the expression of secondary response genes in cardiac myocytes is activated, which include ␤-MHC, ANF, S ⅐ ␣ ⅐ actin, myosin light chains, and so forth. These genes are all "fetal-type genes," which are expressed at high levels in the embryos, and their expression decreases or even ceases after birth. Their expression is responsible for the changes of morphology and function of the heart during cardiac remodeling (10, 14) .
At the protein level, Sodiahima and Izumo (24) reported that, by incubating cultured neonatal rat cardiac myocytes with 100 nM ANG II for 5 days, the expression of ␤-MHC increased dramatically, similar to our findings. During the induction of cardiac hypertrophy, the ratio of ␤-MHC to ␣-MHC mRNA increased because of the enhanced expression of ␤-MHC, and the ratio has been a marker at the molecular level in cardiac hypertrophy and remodeling (14) .
In our experiments, atRA treatment has no detectable effect on ANG II-induced decrease in the ratio of ␤-MHC-to-␣-MHC. However, Rohrer et al. (22) reported that treating cardiac myocytes with similar concentrations of atRA for 16 h increased the expression of the ␣-MHC gene significantly. The differences between Rohrer et al.'s study and ours are that, besides the levels (protein and mRNA) and time points studied, in Rohrer et al.'s experiments, thyroid-free serum was used in cell culture. In such a culture medium, the ␣-MHC gene is hardly expressed and ␤-MHC is predominant. So if there is an increase in ␣-MHC gene expression, it will be easier to detect.
Ultramicroscopic structure. Cultured in the serumfree medium, cardiac myocytes show a dispersed myofiber and nontypical sarcomeric unit. In response to hormones or growth factors such as ANG II, there will be an accumulation of contractile proteins (including myosin light chain 2 , S⅐ ␣ ⅐ actin, MHCs, and so forth) and myofibrillar organization (9, 31) . These events corresponded to the pressure overload or the hormoneand growth factor-induced cardiac hypertrophy and remodeling.
In the human hypertrophied myocardium, channels of granular endoplasmatic reticulum, well-developed Golgi complex, and appearance of nonparallel myofibers are all documented (12) . The observed increase of the Golgi complex and nonparallel myofibers in the cells after ANG II treatment showed that similar ultramicroscopic changes with those in vivo are found in our cell model. atRA can inhibit the increase in the Golgi complex after ANG II treatment in our experiments, and it may be one clue of the inhibitory effect of atRA on protein synthesis. However, atRA has no detectable effects on the ratio of the reorganization of sarcomeric unit.
Intracellular Ca 2ϩ levels. It has been shown that Ca 2ϩ may be an initiator of cardiac hypertrophy and participate in the signal pathway activated by ANG II and ET-1 (21) .
Increase in the extracellular Ca 2ϩ concentration, activator of Ca 2ϩ channel, and electric stimuli all can cause an elevation in the intracellular Ca 2ϩ concentration and further induce cardiac hypertrophy and remodeling. Moreover, decreased capacity of reception of Ca 2ϩ by the sarcoplasmic reticulum and the elevation of the basal intracellular Ca 2ϩ are both correlated with the induction of cardiac hypertrophy and heart failure (4, 6, 17) . During the transition from cardiac hypertrophy to heart failure, there is a dramatic increase in the intracellular Ca 2ϩ in the diastolic phase and dysfunction in the diastolic phase of the heart (1, 3) .
ANG II can induce the increase in Ca 2ϩ concentration either by activating the L-type calcium channel or releasing calcium stored in the sarcoplasmic reticulum (1, 2, 16) .
In human epidermal fibroblasts, release of stored Ca 2ϩ alone is enough to activate the extracellular signal-regulated kinase, which is an important or even essential signal molecule in cardiac hypertrophy (5, 7, 35) . The recent study on the role of Ca 2ϩ and nuclear factors of activated lymphocytes in the hypertrophic responses showed that Ca 2ϩ -dependent pathways are very important signaling pathways in the induction of cardiac hypertrophy (20) .
Currently, there are very few reports on the effect of atRA on intracellular Ca 2ϩ . Varani et al.'s study (32) on the dermal fibroblasts showed that treatment of the cells with atRA alone did not alter the concentration of intracellular Ca 2ϩ resulting from changes in extracellualr Ca 2ϩ concentration. They further documented that this inhibitory effect was due to interference of Ca 2ϩ movement across the plasma membrane, and it was specific for Ca 2ϩ and has no effect for Ba 2ϩ . In the present study, atRA inhibited the ANG IIinduced increase in the intracellular Ca 2ϩ concentration in the cardiac myocytes. This inhibition is a direct evidence that atRA interfers with the transduction pathways stimulated by ANG II, and it might account for the inhibitory effects of atRA on cardiac hypertrophy and remodeling.
The present study showed for the first time that atRA could attenuate ANG II-induced changes of cultured cardiac cells, suggesting a possibility of a new approach for cardiac hypertrophy. Further investigations should be performed to elucidate the mechanism of actions of atRA on cardiac cells as well as to demonstrate the effect of atRA on cardiac hypertrophy in vivo.
